Ke Ding

63PUBLICATIONS

87CO-AUTHORS

Predictive and prognostic markersCheminformatics and quantitative structure-activity relationshipsCharacterisation of biological macromoleculesMolecular targetsBiomolecular modelling and design

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (63)

Sort by Publication Date:

|Jul 07, 2026

A ligandable PNT domain establishes ERG as a directly targetable oncogenic driver in prostate cancer.

|Jun 08, 2026

Structure-Based Design and Optimization of Novel, Potent and Selective Covalent FGFR2/3 Inhibitors with a Tricyclic Core.

|May 29, 2026

Discovery of a Potent, Selective and In Vivo Active Aurora A PROTAC Degrader from a Promiscuous Kinase Inhibitor.

|Mar 19, 2026

Structure-Based Design of Potent and Highly Selective NUAK1 Inhibitors by Exploiting a Unique Glutamate Switch for the Prevention of Tumor Growth, Migration, and Invasion.

Shan Li, Yingao Wang, Xuechen Liu

|Jan 31, 2026

Enhancing Drug Repurposing with Consensus Docking: Discovery of Novel Discoidin Domain Receptor 1 Inhibitors.

Jochem Nelen, Lijie Zhao, Xiaojuan Song

|Oct 06, 2025

Chemical Adaptation in Drug Discovery: The Medicinal Chemistry Journey of Olverembatinib and Limertinib in Overcoming Kinase Drug Resistance.

Ke Ding, Yupeng Li, Yang Zhou

Pageof 11

Frequent Collaborators

18 joint publications

Zhen Wang

15 joint publications

Xiaoyun Lu

13 joint publications

Yang Zhou

Zhengqiu Li

Fengtao Zhou

Weixue Huang

Zhi-Min Zhang

Zhang Zhang

Shan Li